Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Oncology

RayzeBio reaps $108 million for radiotherapies

by Ryan Cross
June 18, 2021 | A version of this story appeared in Volume 99, Issue 23

 

San Diego–based radiopharmaceutical developer RayzeBio has raised $108 million in series C financing, bringing the start-up’s funding to $258 million since it launched in August 2020. RayzeBio is developing macrocycle peptide mimetics that target tumors and deliver radioactive actinium-225. That radioisotope emits α particles that damage nearby cancer cells. AstraZeneca, Bayer, and Novartis have recently made their own investments in experimental therapies that deliver α particle–emitting radioisotopes to tumors.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.